View in EDS HTML Full Text PDF Full Text

Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK.

Saved in:
Bibliographic Details
Title: Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK.
Authors: Chang, Long-Sheng1 (AUTHOR) Long-Sheng.Chang@nationwidechildrens.org, Oblinger, Janet L.1 (AUTHOR), Smith, Abbi E.2 (AUTHOR), Ferrer, Marc3 (AUTHOR), Angus, Steven P.2,4 (AUTHOR), Hawley, Eric2 (AUTHOR), Petrilli, Alejandra M.5 (AUTHOR), Beauchamp, Roberta L.6 (AUTHOR), Riecken, Lars Björn7 (AUTHOR), Erdin, Serkan6 (AUTHOR), Poi, Ming8 (AUTHOR), Huang, Jie1 (AUTHOR), Bessler, Waylan K.2 (AUTHOR), Zhang, Xiaohu3 (AUTHOR), Guha, Rajarshi3 (AUTHOR), Thomas, Craig3 (AUTHOR), Burns, Sarah S.1 (AUTHOR), Gilbert, Thomas S. K.4 (AUTHOR), Jiang, Li2 (AUTHOR), Li, Xiaohong2 (AUTHOR)
Source: PLoS ONE. 7/15/2021, Vol. 16 Issue 7, p1-25. 25p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:19326203
DOI:10.1371/journal.pone.0252048